Amica Mutual Insurance Co. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Amica Mutual Insurance Co. bought a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,350 shares of the company’s stock, valued at approximately $151,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Rhumbline Advisers grew its position in ARS Pharmaceuticals by 2.9% in the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock worth $687,000 after purchasing an additional 1,824 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $217,000 after buying an additional 1,962 shares during the period. LPL Financial LLC lifted its stake in shares of ARS Pharmaceuticals by 11.4% in the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company’s stock valued at $226,000 after buying an additional 2,190 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in ARS Pharmaceuticals by 4.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 80,641 shares of the company’s stock worth $851,000 after buying an additional 3,433 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in ARS Pharmaceuticals by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company’s stock valued at $4,510,000 after acquiring an additional 3,530 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY opened at $12.60 on Thursday. The business has a fifty day moving average of $12.14 and a two-hundred day moving average of $13.07. ARS Pharmaceuticals, Inc. has a 52-week low of $7.55 and a 52-week high of $18.51. The stock has a market cap of $1.22 billion, a PE ratio of -24.71 and a beta of 1.03.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million for the quarter, compared to the consensus estimate of $15.46 million. Analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SPRY has been the topic of several recent research reports. Oppenheimer started coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Leerink Partners increased their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Finally, Raymond James increased their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.00.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $11.10, for a total value of $555,000.00. Following the completion of the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,334,840.60. The trade was a 19.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 159,600 shares of company stock valued at $1,866,516 in the last three months. 40.10% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.